Mark D. Tyson, II, MD, MPH
Advertisement
Mark D. Tyson, II, MD, MPH, is a urologic oncologist at Mayo Clinic.
Articles by Mark D. Tyson, II, MD, MPH
Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.
Advertisement
Latest Updated Articles
Dr Tyson on Factors Influencing the Selection of Nadofaragene Firadenovec in BCG-Unresponsive NMIBCPublished: March 25th 2025 | Updated:
Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPHPublished: May 1st 2025 | Updated:
Dr. Tyson on Rationale For Neoadjuvant Chemotherapy in Bladder CancerPublished: March 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5